Compare APPN & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APPN | TARS |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.8B |
| IPO Year | 2017 | 2020 |
| Metric | APPN | TARS |
|---|---|---|
| Price | $40.66 | $79.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $38.40 | ★ $73.63 |
| AVG Volume (30 Days) | ★ 956.3K | 446.7K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $690,755,000.00 | $366,100,000.00 |
| Revenue This Year | $15.42 | $139.46 |
| Revenue Next Year | $11.07 | $49.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 15.96 | ★ 182.44 |
| 52 Week Low | $24.00 | $38.51 |
| 52 Week High | $46.06 | $83.47 |
| Indicator | APPN | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 58.52 | 63.72 |
| Support Level | $39.70 | $77.44 |
| Resistance Level | $42.76 | $83.47 |
| Average True Range (ATR) | 1.73 | 3.59 |
| MACD | -0.49 | 0.14 |
| Stochastic Oscillator | 21.64 | 70.59 |
Appian Corp is a low-code enterprise platform-as-a-service company focusing on business process management. The company's Appian platform is an integrated automation platform providing tools for organizations to design, automate, and optimize end-to-end processes and complex business operations. Capabilities include case management, robotic process automation, artificial intelligence, data fabric, and process mining. The company also provides maintenance and support as well as consulting services and training related to its platform. The majority of its revenue is subscription-based with the remainder from services, with much of its subscription revenue being derived from its cloud-based platform. Geographically, the company derives maximum revenue from its business in the United States.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.